Pain Review Course with CME
Release Date: February 18, 2018
Expiration Date: February 18, 2020
Statement of Need
Dannemiller is an organization dedicated to the presentation of postgraduate education courses for the purpose of update and review of all areas in the specialties of anesthesia and pain management. For more than a decade, Dannemiller has sponsored numerous CME activities in the area of pain management. As a result of this experience, Dannemiller has had the opportunity to recruit the experts from all of the disciplines involved in pain management. Through evaluation of the Outcomes Studies Reports of these previously sponsored activities, which incorporated feedback from both attendees and experts, Dannemiller has carefully planned this CME activity to provide information that will enhance the attendee's ability to recognize, evaluate, and treat the patient with chronic pain.
This educational activity is intended for pain medicine specialists preparing for certification or re-certification in Pain Medicine and other allied health care professionals interested in expanding their knowledge and improving their practice in pain medicine.
The overall goal of this course is to provide information and increase your ability to recognize, evaluate and effectively treat acute and chronic pain. The course is designed to benefit pain physicians, general anesthesiologists, pharmacists, CRNA’s, nurse practitioners and other health care professionals through a series of in-depth lectures and Q&A sessions headed by faculty and other leaders in the medical field.
Upon completion of this activity, the participant should be able to:
- Identify painful entities, both regional and generalized, and their anatomical and pathophysiological basis for diagnosis and treatment.
- Develop strategies for pharmacological intervention in pain states based on sound pharmacological principles.
- Explain the anatomical and physiological basis of painful states and their management.
- Describe the place of interventional pain management procedures in pain management based on evidence-based medicine.
- Describe the ethical and legal requirements for undertaking pain management
Topic-specific educational objectives are listed at the beginning of each lecture.
Method of Participation
This activity should take approximately 48 hours to complete but learners may take the sessions at their own pace; the system will automatically save a participant’s progress. Participants should first read the objectives and other introductory CE information before proceeding to the educational activity. To receive credit for this activity, participants must complete a post-test with a score of no less than 80%. No re-tests will be allowed if the participant scores less than 80%. Credit is provided through February 18, 2020. No credit will be given after this date.
In the event you have questions about this activity or are unable to retrieve the certificate, please e-mail firstname.lastname@example.org and a certificate will be emailed within 2 weeks.
In support of improving patient care, Dannemiller is jointly accredited by the Accreditation council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Dannemiller designates this live activity for a maximum of 48.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Dannemiller designates this educational activity for 48.00 contact hours.
Dannemiller is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners: AANP Provider Number 090419. This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards. It provides 48.0 of continuing education (which includes 9.0 hours of pharmacology).
This program has been prior approved by the American Association of Nurse Anesthetists for 48.00 Class A CE credits; Code Number 1035623; Expiration Date 2/18/2020.
AANA designates this program as meeting the criteria for up to 8.00 CE Credits in pharmacology/therapeutics.
Clinical Professor of Neurology
University of Missouri School of Medicine
Kansas City, Missouri
Professor of Anesthesiology
Professor and Chairman
Department of Anesthesiology
Advocate Illinois Masonic Medical Center
Pain and Rehabilitation Institute of Montclair
Professor of Clinical Anesthesiology and Medicine
David Geffen School of Medicine at UCLA
Director, UCLA Pain and Spine Care
Los Angeles, California
Department of Radiology
Northwestern University School of Medicine
Director of Pain Management
Advocate, Illinois Masonic Medicine Center
Assistant Professor of Anesthesiology
University of Illinois at Chicago Medical Center
Professor and Program Director
Department of Neurosurgery
University of Michigan Health System
Ann Arbor, Michigan
UT Health Science Center
San Antonio, Texas
Assistant Professor of Anesthesiology
Feinberg School of Medicine
Professor of Anesthesiology and Pharmacology
Vice Chairman for Research
Department of Anesthesiology
University of California
San Diego, California
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), Dannemiller requires that any person, who is in a position to control the content of a CME activity, must disclose all relevant financial relationships they have with a commercial interest. Accordingly:
Dr. Abrams, Dr. Doleys, Dr. Rodes, Dr. Sagher, Dr. Nagpal, Dr. Candido, and Dr. Rana reported they have no financial interest to disclose.
Dr. Liu reports he is an Investigator for Guerbet
Dr. Ferrante reports he serves as a member of the Advisory/Medical Board for Medtronics
Dr. Yaksh reported the following disclosures: Contract research for Advance Targeting Systems, Epigen Biosciences, Sorrento Therapeutics, ARK Animal Health, Medtronic, Asana Biosciences, Alyryx Inc., Aptinyx, Ipsen Innovations, and Sanford Consortium – Scientific Advisory Board for Scintilla Pharmaceuticals and Sorrento Therapeutics – Consultant for Kalyra, Teva, Shionigi Inc., and Sea Pharmaceuticals.
Amber Johnston, Project Manager; Scott Courtney, A/V, and Maria Courtney, Meetings Manager, have no financial relationships with commercial interests.
To resolve identified conflict of interest, the educational content was fully peer reviewed by the Course Director, Dr. Bernard Abrams, who has no relationship with a commercial interest. The resulting certified activity was found to provide educational content that is current, evidence-based, and commercially balanced.
Off Label Statement
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Dannemiller. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
- Computer or smart phone with internet access
- HTML5 compatible browser or Adobe Flash Player